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Abstract
Background and purpose: Papillon treatment is a form of contact X-ray brachytherapy (CXB)
which is used as an alternative to surgery for rectal cancer. This study aimed to audit patients
who were referred for and treated with CXB over a 6-year period against guidelines derived
from a critical review of the evidence base.
Materials and methods: Patient demographics, tumour characteristics and outcome data were
gathered for 31 patients referred for CXB. A critical review of the evidence identified consensus
referral criteria and outcome data against which to audit patients.
Results: Referral criteria were derived from six published studies. These applied to patients unfit
for surgery or stoma-averse. All referred patients had a visible tumour or scar with a tumour size
under 3 cm and sited less than 12 cm from the anal verge. Nodal status varied from N0 to N2,
but there was no metastatic disease present. The audited cohort demonstrated demographic
equivalence, while the initial clinical complete response and recurrence rates were also
comparable.
Conclusion: This audit confirmed the validity of referral and treatment protocols and should
guide future referrals until evidence from ongoing studies becomes available. These findings
should contribute to the development of robust national guidelines.
Introduction
The ‘Papillon’ technique of contact X-ray brachytherapy (CXB) uses 50-kV X-rays to deliver up
to 30 Gy per fraction to treat early-stage rectal tumours. It is delivered fortnightly over three or
four fractions, via a treatment rectoscope under direct vision using dedicated machines such as
the Papillon 50 (Ariane, Alfreton, UK). The technique is associated with no mortality and
very little morbidity,1 aside from short-term bleeding in around 26% of patients.2 Although
the technique has been around for over 80 years, it has recently seen a resurgence in the UK
as a viable treatment option. Colorectal cancers are currently the fourth most common type
of cancer in England, with 27% of these being rectal cancers.3 The number of these patients
deemed suitable for CXB is increasing due to improved availability of CXB in the UK and
increased early detection from screening.4,5
The National Institute for Health and Care Excellence currently supports the use of this pro-
cedure only for early-stage rectal cancer for which surgery is unsuitable or has been declined6
due to a lack of high-quality evidence regarding efficacy. Although there is currently only
one-level 1b randomised controlled trial for CXB, the phase 3 OPERA trial is currently open.7
The current gold standard for treating rectal cancer is surgery, which has considerable mortality
and morbidity for elderly patients8 and results in a permanent stoma in about a third of
patients.2 Avoidance of a permanent stoma is an important outcome measure with great impact
on patient quality of life.9 The need for a standardised set of criteria to guide CXB referral is
becoming essential, yet the dearth of published data means that centres are instead relying
on clinician experience and expertise.
The aim of this audit is to assess whether the correct categories of patients were referred for
CXB treatment from a major cancer centre. Results from this audit could inform and guide
future referral choices. The lack of guidelines meant that published data had to be collated
to provide a standard for comparison. Referral guidelines are an important aspect of
evidence-based practice, and this paper aimed to highlight key referral criteria to help inform this.
Methods
This study required a two-phase approach commencing with a preliminary literature review
gathering published data in lieu of national guidelines. The second phase comprised an audit
of referral patterns and outcomes against the published data.
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Phase one: literature review
A search utilising variations and combinations of the keywords
‘Papillon therapy’ and ‘Rectal cancer’ was performed throughout
the Medline, Scopus and Web of Science databases using
the inclusion and exclusion criteria summarised in Table 1.
Screening and quality assessment were performed as per the
Preferred Reporting Items for Systematic Reviews and Meta-
Analyses10 guidelines and summarised in Figure 1. The remaining
papers were considered the most relevant and highest quality
evidence available to be included in the review. These were then
analysed to extract patient and tumour characteristics data and
outcome data for the cohort treated in each study. Outcome data
comprised median follow-up, initial complete clinical response
(cCR) rate, local recurrence (LR) rate after cCR (including after
salvage surgery), local control (LC) after cCR, rate of distant
metastases and overall survival (OS).
Phase two: audit
The patient cohort comprised patients referred and treated
with CXB between 2013 and 2019. Extracted data included
TNM staging, tumour location and differentiation, patient age
and performance status (PS). Dates and results of the most
recent radiological assessment were also included, along with
cause of death (where appropriate) and any additional treat-
ment received if local or distant progression was developed.
Rationale for patient referral was extracted to identify those
who were not suitable for surgery or wanted to avoid a stoma.
All referred patients received CXB treatment at another
regional centre, and the treatment was delivered according to
departmental protocol. This consisted of 30 Gy of 50-kV X-rays
delivered at each visit, using a Papillon 50 machine, as an
outpatient every 2 weeks, with most patients receiving a total
of 90 Gy delivered in three fractions over 4 weeks.11 All patients
were also prescribed either short-course radiotherapy of 25 Gy
in 5 fractions over 5 days or long-course radiotherapy of 45 Gy
in 25 fractions over 35 days, with or without concurrent chemo-
therapy. Palliative patients were excluded from the cohort to
ensure accurate comparison with the published data. The
project was approved by the Clinical Governance Committee
as a retrospective audit with no requirement for ethical
clearance.
Results
Development of criteria
Referral and outcome data were gathered from five papers relating
to six cohorts as summarised in Tables 2 and 3. All five of the
included papers agreed that to be eligible for Papillon treatment,
the patient must have a visible tumour or post-excision scar as a
target at which to direct the CXB boost.11,12 Tumours from stage
Tis-T4 were all treated across the five studies, with the main limi-
tation mentioned being the size of the tumours, as bulkier tumours
are difficult to treat due to a limitation arising from the maximum
physical size of the treatment applicator.13 Three of the five papers
agreed that the maximum tumour size treatable with CXB was
3 cm,11,13,15 whereas two treated larger tumours, one treating up
to 4 cm12 and the other did not specify a maximum size, but
explained tumours over 3 cmwere treated using overlapping fields.
All papers agreed that patients with tumours larger than their
maximum size treated by CXB could have external beam radio-
therapy tumour debulking prior to CXB dose boost. All studies
included patients with and without nodal involvement at the
time of diagnosis (N0–N2). The maximum distance from the
anal verge of the tumour treated by CXB was either ≤10 cm12,15
or ≤12 cm.11,13,14
Where the information was given (n= 4), all papers treated well
to poorly differentiated tumours, with themajority of tumours well
or moderately differentiated.11–13,15 Similarly, the same papers
included PS of patients (n= 3) and treated patients of any PS
(PS0-3). No patients with metastatic disease were included in
any of the studies, though three of the papers did state that patients
with M1 disease and other patients who could not be treated with
curative intent were treated palliatively using CXB.11,13,15 The
median age of patients across the studies was comparable with a
wide age range of 30–94 across all studies.
All papers included patients with inoperable tumours, those
opted against surgery due to the associated morbidity and possible
mortality and those who refused a stoma. Although not all studies
included how many operable patients were treated with CXB, four
out of the five papers indicated that the majority of patients treated
were operable, with CXB treatment chosen to increase the chance
of organ preservation and stoma avoidance.12–15
The limited number of papers reflects the fact that Papillon
technique is not regarded as a standard of care for rectal cancer,
with only four centres in the UK currently offering CXB.16 All
the papers suffered from the same limitation of being retrospective
studies which may have some degree of selection bias. Despite
these shortcomings, all papers met the inclusion criteria and,
due to the lack of any large multi-centre randomised trial,
represent the highest quality of relevant evidence available at this
time. From these results, a list of criteria for radical intent CXB
treatment was derived for the audit as shown in Table 4.
Audit results: patient characteristics
Over the audit period, 45 patients were referred for CXB treatment;
of these, 5 were excluded as they were still undergoing Papillon
treatment, and 9 were excluded as they were being treated with
palliative intent. A study size of 31 patients may be considered a
relatively small cohort, but 2 of the comparator cohorts had similar
numbers (n= 40, n= 45) and 1 had fewer (n= 17). Patient
demographics can be seen in Table 2; the median age of patients
referred was 73, which was within a year of the median age of 4
of the 6 cohorts. Of the other two cohorts, one had a higher median
age and one was lower. The gender ratio was similar across all stud-
ies, withmale being themajority in all of them. PS was not included
in all published data, although most patients were PS 0–1, which
matched with the audit cohort. One of the criteria for referral iden-
tified above was that the patient was unsuitable for surgery or had
refused surgery to avoid a stoma. Only two of the studies included
Table 1. Literature review inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
English language
2008 onwards
Full article available
Relates to radical CXB
Includes patient referral data
Includes outcome data
Lack of a patient cohort
Abstracts only
Any CXB not used to treat rectal cancer
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the proportion of patients who were considered operable, so these
data were not included in Table 2. The audit cohort identified 42%
of patients as unfit for surgery, compared to 57% described as
either inoperable or high risk in one study12 and 27% described
as inoperable in another.15
Audit results: tumour characteristics
Differentiation of tumour data was available in five of the six
cohorts. However, in all five of these, a significant proportion
was not known (17·7–31·5%). The majority of the audited cohort
presented with moderately differentiated tumours (96·8%), which
was higher than all the comparators; but, in all cohorts, well to
moderate differentiation was the majority. The audit cohort had
pre-treatment tumour stages between T1 and T3, while most of
the tumours in all cohorts were stage T2 or T3. Nodal status
was predominantly N0 in all studies with the audited cohort
reporting 83·9% N0 nodal stage. No patients with metastatic dis-
ease were included in any of the cohorts.
Audit results: outcome data
Median follow-up of all seven cohorts ranged from 20 to 64
months with the audit cohort towards the shorter end at 22
months. Initial cCR, LR, sustained LC, metastatic spread and OS
rates were compared. An ‘initial cCR’ was defined as following
CXB but before any necessary salvage surgery. The rate of initial
cCR for the audit cohort was high at 93·6%; this was similar to three
of the six comparator groups. The LR rate after cCR included
recurrence in all patients considered to have achieved a cCR fol-
lowing CXB and any necessary salvage surgery. A total of 20·7%
of the audit cohort experienced LR for which no further treatment
was possible; this was comparable to the reported rates which
ranged from 11 to 27%. Sustained LC in the audit cohort was
achieved for 25 of the 31 (80·6%) patients referred for CXB which
is similar to 2 of these comparator cohorts with the other 3 cohorts
reporting both higher and lower rates (60–95%). The rate of distant
metastases was relatively low within the reported data, ranging
from 8·5 to 20·5%, while the audit cohort rate was 13·8%.
Finally, it was encouraging to see the audit cohort reporting the
highest rate of OS at 83·9%, with one study reporting a similar rate
of 82%14 and the others ranging from 60 to 73%. Figure 2 shows the
Kaplan–Meier plot for this within the studied cohort.
Discussion
Referral criteria
The different distribution of tumour (T) stage across the published
evidence can partly be attributed to selectivity of studies with
papers only reporting a specific cohort. However, and importantly
for the validity of the outcome data, two papers found that stage of
tumour was not a prognostic factor for achieving a cCR or for sur-
vival.11,13 Similarly, though nodal stage of patients was distributed
differently in the audit cohort, with more N0 than other
studies, this was also found to not be related to chance of achieving
a cCR or local regrowth rates.11,13
While PS and age in the audit cohort were similar to the other
studies, it did include more PS 0 patients than any of the other
studies. Although PS and age were not found to be indications
for cCR rate,11 one paper did report them as factors for
disease-free survival (both p≤ 0·001).13 This possibly reflected
the median age and thus the likelihood of patient comorbidities
as well as patient tolerance to external beam radiotherapy.17 It is
likely, therefore, this higher proportion of PS 0 patients might have
contributed to the higher OS reported in the audit cohort.
Figure 1. PRISMA flow diagram.
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The underlying rationale for referral proved challenging to
audit for several reasons. Firstly, not all of the studies included
these data, despite all of them indicating that one of the main rea-
sons for a CXB boos was to improve the rate of organ preservation
and reduce permanent stoma risk.11–15 Secondly, the criteria for
patients either being unfit for surgery or inoperable were unclear
and may have been reported differently for each study. This is a
limitation for the study as having a higher proportion of operable
patients who can undergo possible salvage surgery may improve
overall LC rates for that cohort.
Table 3. Comparison of outcome data
Audit cohort Myint 201811 Frin 201712 Myint 201713 Smith 201614 Gerard 201515 Gerard 201515
Cohort size 31 83 45 200 17 80 40
Median FU 22 months 30 months 60 months 32 months 20 months 64 months 63 months
FU range 4–55 months 14–100 months NR NR 5–54 months NR NR
cCR 29 (93·6%) 53 (64·8%) 43 (96%) 144 (72%) 9 (53%) 75 (94%) 38 (95%)
LR 6 (20·7%) 6 (11·4%) 11% 16 (11%) NR 22 (27%) 4 (14%)
LC 25 (80·6%) 69 (83·1%) NR 80·5% 60% 73% 95%
Mets 4 (13·8%) 7 (13·2%) 17% 17 (8·5%) NR 10 (17%) 8 (20·5%)
OS 26 (83·9%) 56 (67·5%) 64% at 3 years 136 (68%) 82% 73% 60%
Abbreviations: FU, Follow-up; NR, not reported or unknown; cCR, Initial complete clinical response; LR, Local recurrence after cCR (including after salvage); LC, Local control; Mets, Presence of
distant metastases; OS, Overall survival.
Table 2. Comparison of referral data
Audit Myint 201811 Frin 201712 Myint 201713 Smith 201614 Gerard 201515 Gerard 201515
Cohort size (n) 31 83 45 200 17 80 40
Median age Years 73 72 74 74 65 73 81
Age range Years 47–90 36–87 30–93 32–94 47–84 NR NR
Gender Females (%) 32·3 30·1 28·8 33·0 11·8 30 27·5
Males (%) 67·7 69·9 71·1 67·0 70·6 70 72·5
NR (%) 0 0 0 0 17·6 0 0
Performance status 0 (%) 54·8 42·2 – 33·0 –
1 (%) 22·6 41·0 – 36·5 – 48·6 77·5
2 (%) 19·4 10·8 – 20·5 –
3 (%) 3·2 3·6 – 3·5 – 30 22·5
NR (%) 0 2·4 100 6·5 100 21·3 0
Differentiation Well (%) 0 3·6 40 5·0 – 45 35
Moderate (%) 96·8 69·9 37·7 60·5 – 28·8 40
Poor (%) 3·2 1·2 4·4 3·0 – 3·8 5
NR (%) 0 25·3 17·7 31·5 100 22·5 20
Tumour stage T1 (%) 19·4 0 4·4 10·5 11·8 5 7·5
T2 (%) 41·9 33·7 51·1 44·5 17·6 60 47·5
T3 (%) 38·7 66·3 44·5 43·5 47·0 35 45·0
T4 (%) 0 0 0 1·5 – 0 0
NR (%) 0 0 0 0 17·6 0 0
Nodal stage N0 (%) 83·9 45·8 73·3 62·5 41·2 75 72·5
N1 (%) 16·1 38·6 22·2 28·0 11·8 25 27·5
N2 (%) 0 14·5 4·5 9 23·5 0 0
NR (%) 0 1·2 0 0·5 17·6 0 0
Metastases M0 (%) 100 100 100 100 100 100 100
Abbreviation: NR, not reported or unknown.
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Overall, the patient and tumour characteristics of the audit
cohort were similar in many ways to those of the cohorts reported
in the published data. This suggested that, based on these criteria,
referrals within the audit aligned well with current best evidence.
This also indicated that comparison of outcome data would be valid.
Patient outcomes
Although cCR was used for comparing outcomes, the exact
method and criteria used for assessing this were not explained well
in all the papers and may have even changed with time or inves-
tigator expertise. This issue was acknowledged and within another
recent paper which described how to accurately assess response to
CXB.18 This possible limitationmay explain the difference in initial
cCR rates reported across the studies.
LR rate was similar across all seven cohorts, which is significant
because this was found to be independent of PS, age, tumour stage,
nodal stage, distance from anal verge, tumour size or treatment
method.13 The rate of distantmetastaseswas higher in all of the stud-
ies with longer follow-up lengths, which may indicate time could be
a factor for this outcome; however, one studywith a longer follow-up
time had a lower rate of distant metastases than the audit cohort.
Although it was difficult to make an accurate comparison of out-
come data for all the reasons explored above, many of the outcomes
of the audit cohort were comparable to published studies, especially
LR after cCR, which reaffirms referral criteria. It is recommended
that the audit be repeated after a longer follow-up period to ensure
the outcome comparisons remain valid. Further work will also
include stoma-free survival and bowel function data for all patients
treated with CXB as this is highlighted in the literature as an impor-
tant outcome and one of the main reasons that CXB is used over
non-conservative surgical treatment. Like other recent studies have
noted, evidence suggests that CXB treatment is indicated as a good,
potentially organ preserving alternative to surgery for older, co-
morbid patients who are inoperable or high surgical risk, as well
as younger, stoma-averse patients, and has good cCR and LR
rates.11–13 It is recommended that the national guidelines be
updated to reflect this growing body evidence.
Limitations
As well as the limitations described above, this study has several
other constraints. Firstly, as this study was a retrospective audit,
the only data available at the time of review could be used.
These data may include an unknown number of referred patients
who were deemed unsuitable and rejected by the treating depart-
ment. Criteria development was based on the strongest available
current evidence, but all studies used had their own acknowledged
limitations. In general, these were selective, retrospective, mono-
centric reviews over time periods where treatment techniques,
assessment methods and equipment may have changed.
Conclusion
The results of this audit demonstrated that the demographic and
pathological profile of the referred patients matched those reported
in the literature. The similarity of the cohorts enabled comparison
of outcome data which confirmed the validity of referral and treat-
ment protocols. Although the limited evidence base and retrospec-
tive nature of the audit limit the strength of the findings, this work
should guide future referrals until evidence from ongoing studies
becomes available and can also be used to inform future audits
undertaken in this area. It is also anticipated that the reviewed evi-
dence presented here will contribute to the development of robust
national guidelines.
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